Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor's immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.
Properties:
Density: 2.087g/cm3
Boiling Point: 979.004ºC at 760 mmHg
Flash Point: 545.882ºC
Refractive Index: 1.722
Vapor Pressure: 0mmHg at 25°C